News >

Burgess Shares Insight on Evolving Prostate Cancer Paradigm

Brandon Scalea
Published: Wednesday, Oct 31, 2018

Earle Burgess, MD

Earle Burgess, MD

Recent clinical trials and regulatory decisions have shifted treatment for patients with metastatic castration-sensitive prostate cancer, but tireless research needs to continue until curative strategies emerge, said Earle Burgess, MD.

One of the latest advances was the February 2018 FDA approval of abiraterone acetate (Zytiga) in combination with prednisone for patients with high-risk disease. This approval was based on phase III findings from the LATITUDE study.

In the trial, the combination of abiraterone acetate and androgen deprivation therapy (ADT) led to a 38% reduction in the risk of death compared with ADT alone. After a median follow-up of 30.4 months, median overall survival (OS) was not yet reached with abiraterone acetate compared with 34.7 months with placebo for patients with high-risk metastatic castration-sensitive prostate cancer (HR, 0.62; 95% CI, 0.51-0.76; P <.001).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication